J 2021

Side Effects of mRNA-Based COVID-19 Vaccine: Nationwide Phase IV Study among Healthcare Workers in Slovakia

RIAD, Abanoub, Barbora HOCKOVÁ, Lucia KANTOROVÁ, Rastislav SLÁVIK, Lucia SPURNÁ et. al.

Základní údaje

Originální název

Side Effects of mRNA-Based COVID-19 Vaccine: Nationwide Phase IV Study among Healthcare Workers in Slovakia

Autoři

RIAD, Abanoub (818 Egypt, garant, domácí), Barbora HOCKOVÁ (203 Česká republika), Lucia KANTOROVÁ (703 Slovensko, domácí), Rastislav SLÁVIK (703 Slovensko), Lucia SPURNÁ (703 Slovensko), Adam STEBEL (703 Slovensko), Michal HAVRIĽAK (703 Slovensko) a Miloslav KLUGAR (203 Česká republika, domácí)

Vydání

Pharmaceuticals, Basel, MDPI, 2021, 1424-8247

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30104 Pharmacology and pharmacy

Stát vydavatele

Švýcarsko

Utajení

není předmětem státního či obchodního tajemství

Odkazy

Impakt faktor

Impact factor: 5.215

Kód RIV

RIV/00216224:14110/21:00122210

Organizační jednotka

Lékařská fakulta

UT WoS

000701939600001

Klíčová slova anglicky

BNT162b2 vaccine; cross-sectional studies; COVID-19; drug-related side effects and adverse reactions; health personnel; mass vaccination; prevalence

Příznaky

Mezinárodní význam, Recenzováno
Změněno: 18. 10. 2021 09:46, Mgr. Tereza Miškechová

Anotace

V originále

mRNA-based COVID-19 vaccines such as BNT162b2 have recently been a target of anti-vaccination campaigns due to their novelty in the healthcare industry; nevertheless, these vaccines have exhibited excellent results in terms of efficacy and safety. As a consequence, they acquired the first approvals from drug regulators and were deployed at a large scale among priority groups, including healthcare workers. This phase IV study was designed as a nationwide cross-sectional survey to evaluate the post-vaccination side effects among healthcare workers in Slovakia. The study used a validated self-administered questionnaire that inquired about participants’ demographic information, medical anamneses, COVID-19-related anamnesis, and local, systemic, oral, and skin-related side effects following receiving the BNT162b2 vaccine. A total of 522 participants were included in this study, of whom 77% were females, 55.7% were aged between 31 and 54 years, and 41.6% were from Banska Bystrica. Most of the participants (91.6%) reported at least one side effect. Injection site pain (85.2%) was the most common local side effect, while fatigue (54.2%), headache (34.3%), muscle pain (28.4%), and chills (26.4%) were the most common systemic side effects. The reported side effects were of a mild nature (99.6%) that did not require medical attention and a short duration, as most of them (90.4%) were resolved within three days. Females and young adults were more likely to report post-vaccination side effects; such a finding is also consistent with what was previously reported by other phase IV studies worldwide. The role of chronic illnesses and medical treatments in post-vaccination side effect incidence and intensity requires further robust investigation among large population groups.

Návaznosti

LTC20031, projekt VaV
Název: Towards an International Network for Evidence-based Research in Clinical Health Research in the Czech Republic
Investor: Ministerstvo školství, mládeže a tělovýchovy ČR, Towards an International Network for Evidence-based Research in Clinical Health Research in the Czech Republic, INTER-COST
MUNI/A/1608/2020, interní kód MU
Název: Prohlubování znalostí v oblasti zdravotních rizik a benefitů výživy, prostředí a životního stylu III
Investor: Masarykova univerzita, Prohlubování znalostí v oblasti zdravotních rizik a benefitů výživy, prostředí a životního stylu III
MUNI/IGA/1068/2020, interní kód MU
Název: Methodological and practical aspects of the development of guidelines and rapid guidelines in public health (Akronym: RAPguidelines-public-health)
Investor: Masarykova univerzita, Methodological and practical aspects of the development of guidelines and rapid guidelines in public health
MUNI/IGA/1543/2020, interní kód MU
Název: Evidence-based Practice of Healthcare Professionals and Students in the Czech Republic (Akronym: Evidence-Based Practice in Czechia)
Investor: Masarykova univerzita, Evidence-based Practice of Healthcare Professionals and Students in the Czech Republic